Chronic obstructive pulmonary disease refers to widespread heterogeneous human diseases and has a tendency to increase morbidity. The article presents modern views on the classification, diagnostic criteria and approaches to the treatment of the disease from the standpoint of the Global Initiative on Chronic Obstructive Pulmonary Disease revision 2021. There was an insufficient level of diagnosis of chronic obstructive pulmonary disease by general practitioners and therapists. The role of combined bronchodilatory therapy, a place in the treatment of inhaled glucocorticosteroids is noted.

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report) 2020; 2020. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25... Accessed February2, 2021.

2. Klinicheskie rekomendacii «Hronicheskaya obstruktivnaya bolezn’ legkih», 2021g. Utv. MZ RF.

3. Zider A. D., Wang X., Buhr R. G. et al. Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis // Chest. 2017. Vol. 152. No 3. P. 494–501.

4. Anna D Coutinho, Tasneem Lokhandwala, Robert L Boggs, Anand A Dalal, Pamela B Landsman-Blumberg, Julie Priest, David A Stempel. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population // Int J Chron. Obstruct. Pulmon. Dis. 2016; 11: 1223–1231. Published online 2016 Jun 8. doi: 10.2147/COPD.S102570

5. Guan W. J., Liang W. H., Zhao Y. et al. China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020.

6. Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M. The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis. 2014;9:1397– 1405. doi: 10.2147/COPD.S71370.

7. Miravil’es M., Al’kasar B., Soler-Katalun’ya H. H. Koncepciya kontrolya pri lechenii hronicheskoj obstruktivnoj bolezni legkih: razrabotka kriteriev i validaciya dlya klinicheskogo primeneniya (perevod s anglijskogo). Pul’monologiya. 2020;30(2):142-150. https://doi.org/10.18093/0869-0189-2020-30-2-142-150

8. Avdeev S. N. Koncepciya kontrolya hronicheskoj obstruktivnoj bolezni legkih kak instrument prinyatiya resheniya i optimizacii bazisnoj terapii v real’noj klinicheskoj praktike / S. N. Avdeev, Z. R. Ajsanov, A. S. Belevskij [i dr.] // Terapevticheskij arhiv. – 2020. – T. 92. – № 1. – S. 89–95. – DOI 10.26442/00403660.2020.01.000489.

9. Chuchalin AG, Khaltaev N, Antonov NS, et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963–974. doi: 10.2147/COPD.S67283.

10. Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. doi: 10.1186/s12931-019-1193-9.

11. Donaldson G. C., Seemungal T. A., Patel I. S. et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations // Eur. Respir. J. 2003. Vol. 22. No 6. P. 931–936.

12. Andreeva E., Pokhaznikova M., Lebedev A., Moiseeva I., Kutznetsova O., Degryse J. M. The Prevalence of Chronic Obstructive Pulmonary Disease by the Global Lung Initiative Equations in North-Western Russia. Respiration. 2016;91:43–55. doi: 10.1159/000442887.

13. Lowe KE, Regan EA, Anzueto A, et al. COPDGene 2019: redefining the diagnosis of chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2019; 6(5): 384-399. doi: http://doi.org/10.15326/jcopdf.6.5.2019.0149.

14. De-Torres JP, O’Donnell DE, Marín JM et al. Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. Chest 2021 Volume 160, Issue 3, September 2021, Pages 872-878 DOI 10.1016/j.chest.2021.04.033.

15. Choi, J., Sim, J. K., Oh, J. Y. et al. Prognostic marker for severe acute exacerbation of chronic obstructive pulmonary disease: analysis of diffusing capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in one second (FEV1). BMC Pulm Med 21, 152 (2021). https://doi.org/10.1186/s12890-021-01519-1.

16. Diab N, Gershon AS, Sin DD, Tan WC, Bourbeau J, Boulet LP, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(9):1130–1139.

17. Maltais F, Bjermer L, Kerwin EM et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019 Oct 30;20(1):238. doi: 10.1186/s12931-019-1193-9.